Long-Acting Therapeutics Patents and Licences Database
收藏资源简介：
LAPaL is a repository for information on long-acting (LA) technologies patents and licences. As of Sep 2025, it comprises 37 long-acting platform technologies and 50 LA formulations with many potential applications in the fields of HIV prevention and treatment, hepatitis B treatment, malaria treatment, type 2 diabetes and metabolic disorders management, pain management and contraception, among other applications. In 2023, and through a collaboration with the Center of Excellence of Long Acting Therapeutics and the Long-Acting/Extended Release Antiretroviral Research Resource Program, a new section was added to LAPaL, with 10 compounds with long half-life or that could be formulated in a manner that enables extended release. We are also collaborating with major initiatives and groups, such as AVAC, to synergise efforts and support the global community to deliver effectively in the HIV prevention space. Additionally, a visualisation tool (Landscape) is available for the selection of investigated and approved long-acting compounds in the HIV and TB fields and the related clinical trials. It provides information on the clinical trials pipeline of a set of compounds and filing data for the most advances products.
LAPaL是一款长效（long-acting，LA）技术专利与许可信息资源库。截至2025年9月，该库共收录37项长效平台技术及50种长效制剂，其潜在应用涵盖艾滋病（Human Immunodeficiency Virus，HIV）防治、乙型肝炎治疗、疟疾治疗、2型糖尿病及代谢紊乱管理、疼痛管理与避孕等多个领域。 2023年，通过与长效治疗卓越中心（Center of Excellence of Long Acting Therapeutics）及长效/缓释抗逆转录病毒研究资源计划（Long-Acting/Extended Release Antiretroviral Research Resource Program）开展合作，LAPaL新增专属板块，收录了10种具备长半衰期或可制备为缓释剂型的化合物。 本库还与AVAC等主流倡议组织及团体展开协作，以协同增效，助力全球社群在艾滋病防治领域高效推进相关工作。 此外，平台配备一款可视化工具（Landscape），可用于筛选艾滋病与结核病（Tuberculosis，TB）领域已研究及获批的长效化合物及其相关临床试验。该工具可提供对应化合物的临床试验管线信息，以及前沿产品的申报数据。
